Prof Alistair Nichol (Dublin & Melbourne) discusses why the REMAP-CAP adaptive platform trial has chosen to investigate ivermectin, given the controversy surrounding this agent.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
